Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma (sBCC) in the USBCC is the most common skin cancer in the US with 3.6 million cases diagnosed annually1 WOBURN, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercializa

First dose at HOAG Health in FAPI-PRO trial for Pancreatic Ductal Adenocarcinoma A parallel trial focused on gastroesophageal cancers, FAPI-GO, dosed its first patient December 2025 DULLES, Va., Feb. 11, 2026 /PRNewswire/ -- SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in the second of its two Phase 3 clinical trials evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibr

• World’s first clinical study of a fully standardised, multi-alkaloid DMT–harmala formulation designed for regulated medical use • Acute effect scores on MEQ-30 and 5D-ASC exceeded those reported in prior psilocybin and LSD studies using these standardised measures • Psychedelic effects were strongly associated with persisting psychological benefits, including enhanced wellbeing and more positive life attitudes. • Results support advancement of Neurala’s proprietary second-generation product ca

AstraZeneca is moving its oral, once-daily GLP-1 receptor agonist elecoglipron (AZD5004) into Phase III development for obesity and type 2 diabetes in the hopes of adding another drug to its growing portfolio of blockbusters. The company — alongside announcing its latest financial results on Tuesday — noted that it currently has 16 blockbuster medicines on its hands and is hoping to expand this to over 25 by the end of the decade.In 2024, when AstraZeneca set out its target of growing annual rev

Upstream Bio on Wednesday said its TSLP-targeting drug met its goal in a mid-stage trial in severe asthma, which is a step forward in its bid to challenge Dupixent and Tezspire down the line. The biotech’s verekitug, given at a 100 mg dose every three months, reduced the rate of yearly asthma flare-ups by 56% versus placebo in the study’s primary endpoint. The result was statistically significant, with a p-value of less than 0.0003. In the less frequent regimen, a 400 mg dose once every six mont

HONG KONG, Feb. 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These indications include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe ato

TAINAN, Feb. 9, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive Phase 1 results for TML-6, its investigational oral therapy for Alzheimer's disease (AD). The study demonstrated that TML-6 was generally well tolerated with a favorable safety profile, supporting its continued clinical development. TML-6 is designed to modulate the autolysosomal system and interconnected cellular pathways involved

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment Options Oveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1 The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Admini

BARCELONA, Spain, Feb. 10, 2026 /PRNewswire/ -- Gyala Therapeutics, a clinical-stage biotechnology company developing innovative cell therapies for hematologic malignancies, today announced the initiation of a Phase I/IIa clinical trial of GYA01 following authorization from the Spanish Agency of Medicines and Medical Devices (AEMPS). The study will evaluate GYA01, a first-in-class CAR-T cell therapy targeting the CD84 protein, in patients with relapsed or refractory acute myeloid leukemia (AML)

MUMBAI, India & NAPLES, Fla., Feb. 4, 2026 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the launch of Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, and 200 mg, in the United States, following the approval for its Abbreviated New Drug Application (ANDA) from the U.S. FDA. Topiramate Extended-Release Capsules are bioequivalent to the reference listed drug (RLD), Trokendi XR® Extended-Relea